Copyright
©The Author(s) 2024.
World J Clin Cases. May 6, 2024; 12(13): 2218-2230
Published online May 6, 2024. doi: 10.12998/wjcc.v12.i13.2218
Published online May 6, 2024. doi: 10.12998/wjcc.v12.i13.2218
Table 1 Basic characteristics of included studies
Ref. | Sample size | Male (%) | Age (yr) | Disease duration (yr) | Intervention | Treatment duration (wk) | Left ventricular function | Type of CHF | Baseline cardiac disease |
Bai and Li[19], 2023 | 44 | 54.5 | 62.8 ± 5.3 | 10.6 ± 2.2 | Perindopril, metoprolol, trimetazidine, and YXST (0.18 g tid) | 4 | ICM | ||
44 | 52.3 | 62.0 ± 5.1 | 10.8 ± 2.4 | Perindopril, metoprolol, and trimetazidine | 4 | ||||
Bai[20], 2019 | 50 | 50.0 | 66.6 ± 10.4 | Telmisartan, amlodipine, and YXST (0.18 g tid) | 4 | ICM | |||
50 | 52.0 | 66.5 ± 10.2 | Telmisartan and amlodipine | 4 | |||||
Cheng et al[21], 2019 | 48 | 54.2 | 71.2 ± 3.6 | Levocarnitine and YXST (0.18 g tid) | 1 | Left ventricular diastolic dysfunction | HFpEF | ||
48 | 52.1 | 71.9 ± 3.8 | Levocarnitine | 1 | |||||
Chen[22], 2019 | 20 | 70.0 | 64.0 ± 11.0 | ACEI/ARB, MRA, diuretic, cardiotonic, and YXST (0.18 g tid) | 4 | ||||
20 | 85.0 | 63.0 ± 10.0 | ACEI/ARB, MRA, diuretic, and cardiotonic | 4 | |||||
Fan et al[23], 2020 | 63 | 52.4 | 66.0 ± 3.7 | Optimizing drug therapy and YXST (0.18 g tid) | 48 | ||||
63 | 57.1 | 67.0 ± 3.6 | Optimizing drug therapy | 48 | |||||
Fu et al[26], 2014 | 64 | 65.6 | 65.0 ± 10.2 | 2.4 ± 1.2 | ACEI, diuretic, cardiotonic, and YXST (0.18 g tid) | 12 | NICM | ||
62 | 64.5 | 64.0 ± 10.8 | 2.3 ± 1.4 | ACEI, diuretic, and cardiotonic | 12 | ||||
Gu et al[25], 2016 | 60 | 65.0 | 61.8 ± 11.8 | Perindopril, metoprolol, spironolactone, furosemide, isosorbide mononitrate, aspirin, clopidogrel, atorvastatin, and YXST (0.18 g tid) | 24 | ||||
60 | 70.0 | 62.5 ± 15.3 | Perindopril, metoprolol, spironolactone, furosemide, isosorbide mononitrate, aspirin, clopidogrel, and atorvastatin | 24 | |||||
Gao and Zhang[24], 2021 | 39 | 51.3 | 62.54 ± 7.5 | Benazepril, metoprolol, furosemide, digoxin, and YXST (0.18 g tid) | 24 | ||||
39 | 53.8 | 63.0 ± 6.8 | Benazepril, metoprolol, furosemide, and digoxin | 24 | |||||
Huang et al[27], 2009 | 63 | 58.7 | 59.8 ± 11.2 | 5.2 ± 4.3 | ACEI, β-blocker, diuretic, vasodilator, and YXST (0.18 g tid) | 4 | Left ventricular diastolic dysfunction | HFmrEF, HFpEF | |
62 | 58.1 | 61.2 ± 13.4 | 5.0 ± 4.9 | ACEI, β-blocker, diuretic, and vasodilator | 4 | ||||
Li and Zhou[28], 2019 | 60 | 56.7 | 66.6 ± 12.5 | 5.7 ± 2.1 | Bisoprolol and YXST (0.12 g tid) | 24 | ICM | ||
60 | 43.3 | 64.9 ± 12.3 | 5.7 ± 2.0 | Bisoprolol | 24 | ||||
Li[29], 2017 | 47 | 53.2 | 61.35 ± 8.7 | 9.3 ± 3.6 | Diuretic, vasodilator, trimetazidine, statin, and YXST (0.18 g tid) | 4 | ICM | ||
47 | 51.2 | 61.58 ± 7.6 | 9.52 ± 2.9 | Diuretic, vasodilator, trimetazidine, and statin | 4 | ||||
Liu[30], 2022 | 33 | 48.5 | 58.4 ± 11.5 | 9.5 ± 3.1 | ACEI/ARB, β-blocker, MRA, diuretic, and YXST (0.18 g tid) | 12 | Left ventricular diastolic dysfunction | HFpEF | |
32 | 43.8 | 57.1 ± 12.8 | 10.2 ± 3.7 | ACEI/ARB, β-blocker, MRA, and diuretic | 12 | ||||
Qian and Wei[31], 2012 | 56 | ACEI, β-blocker, diuretic, vasodilator, cardiotonic, and YXST (0.12g tid) | 12 | NICM | |||||
56 | ACEI, β-blocker, diuretic, vasodilator, and vardiotonic | 12 | |||||||
Qu[32], 2008 | 89 | 61.8 | 52.0 ± 13.1 | ACEI, β-blocker, diuretic, vasodilator, cardiotonic, and YXST (0.18g tid) | 24 | ||||
82 | 62.2 | 53.3 ± 18.3 | ACEI, β-blocker, diuretic, vasodilator, and cardiotonic | 24 | |||||
Sun et al[35], 2016 | 34 | 44.1 | 58.0 ± 13.1 | ACEI, β-blocker, diuretic, and YXST (0.18g tid) | 16 | ||||
34 | 52.9 | 54.3 ± 15.3 | ACEI, β-blocker, and diuretic | 16 | |||||
Wang et al[33], 2011 | 34 | 64.7 | Spironolactone, hydrochlorothiazide, nitroglycerin, dobutamine, and YXST (0.24 g tid) | 2 | |||||
26 | 69.2 | Spironolactone, hydrochlorothiazide, nitroglycerin, and dobutamine | 2 | ||||||
Yuan[34], 2012 | 40 | 52.5 | 68.7 ± 10.2 | 3.2 ± 0.7 | ACEI, β-blocker, diuretic, vasodilator, and YXST (0.24 g tid) | 4 | Left ventricular diastolic dysfunction | HFpEF | |
35 | 51.4 | 71.3 ± 13.1 | 2.9 ± 0.9 | ACEI, β-blocker, diuretic, and vasodilator | 4 | ||||
Zhang and Niu[36], 2017 | 34 | 52.9 | 55.7 ± 9.6 | 6.0 ± 3.3 | Benazepril, metoprolol, losartan potassium, hydrochlorothiazide, and YXST (0.18 g tid) | 8 | Left ventricular diastolic dysfunction | HFmrEF, HFpEF | |
33 | 63.6 | 54.1 ± 9.6 | 6.1 ± 3.2 | Benazepril, metoprolol, losartan potassium, and hydrochlorothiazide | 8 | ||||
Zhang[37], 2018 | 30 | 60.0 | 63.8 ± 4.8 | ACEI, β-blocker, MRA, and YXST (0.18 g tid) | 12 | ||||
30 | 56.7 | 62.6 ± 5.2 | ACEI, β-blocker and MRA | 12 | |||||
Zhang[38], 2022 | 27 | 48.1 | 65.2 ± 5.3 | 5.2 ± 1.0 | ARNI/ARB, β-blocker, MRA, diuretic, vasodilator, cardiotonic, and YXST (0.18 g tid) | 8 | HFrEF | ||
27 | 58.6 | 64.1 ± 6.0 | 5.1 ± 1.2 | ARNI/ARB, β-blocker, MRA, diuretic, vasodilator, and cardiotonic | 8 |
- Citation: Lu SH, Yu YF, Dai SS, Hu YQ, Liu JH. Efficacy and safety of Yangxinshi tablet for chronic heart failure: A systematic review and meta-analysis. World J Clin Cases 2024; 12(13): 2218-2230
- URL: https://www.wjgnet.com/2307-8960/full/v12/i13/2218.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i13.2218